William Blair biopharma equity capital markets managing director Kevin Eisele was quoted in Reuters, where he shared his outlook for which industry and macroeconomic factors could support a rebound of the biotech sector’s IPO market in 2026.
“I think for the most part, it just continues to be a lot of headline risk,” Eisele told the publication.